80 mg DR-6MP
C2/13/DR-6MP-02 EXT
Phase 2 small_molecule terminated
Quick answer
80 mg DR-6MP for Crohn's Disease is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Crohn's Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated